Potential Drug-Drug Interaction (PDDI) CDS IG : STU Ballot 1

This page is part of the Potential Drug-Drug Interaction (PDDI) Clinical Decision Support (CDS) (FHIR IG) (v0.1.0: STU 1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v3.5.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

valueset-rimexolone-exclude

Raw json

{
  "resourceType" : "ValueSet",
  "id" : "valueset-rimexolone-exclude",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns="http://www.w3.org/1999/xhtml"><h2>Exclude Rimexolone Medications Value Set</h2><div><p>ValueSet containing drug identifiers to exclude. Criteria is explicitly stating topical, gel, cream, ointment, otic, or ophthalmic formulations.</p>
</div><p><b>Copyright Statement:</b> Attribution CC BY</p><p>This value set includes codes from the following code systems:</p><ul><li>Include these codes as defined in <a href="http://www.nlm.nih.gov/research/umls/rxnorm"><code>http://www.nlm.nih.gov/research/umls/rxnorm</code></a><table class="none"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td>207446</td><td>rimexolone 10 MG/ML Ophthalmic Suspension [Vexol]</td><td/></tr><tr><td>365826</td><td>rimexolone Ophthalmic Suspension [Vexol]</td><td/></tr><tr><td>199115</td><td>rimexolone 10 MG/ML Ophthalmic Suspension</td><td/></tr><tr><td>379299</td><td>rimexolone Ophthalmic Suspension</td><td/></tr><tr><td>1157440</td><td>rimexolone Ophthalmic Product</td><td/></tr><tr><td>1188083</td><td>Vexol Ophthalmic Product</td><td/></tr></table></li></ul></div>"
  },
  "url" : "http://hl7.org/fhir/uv/pddi/ValueSet/valueset-rimexolone-exclude",
  "version" : "0.1.0",
  "name" : "valueset-rimexolone-exclude",
  "title" : "Exclude Rimexolone Medications Value Set",
  "status" : "draft",
  "date" : "2018-07-02",
  "publisher" : "PDDI CDS",
  "contact" : [
    {
      "name" : "Richard Boyce boycerd@upmc.edu"
    }
  ],
  "description" : "ValueSet containing drug identifiers to exclude. Criteria is explicitly stating topical, gel, cream, ointment, otic, or ophthalmic formulations.",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "International"
        }
      ]
    }
  ],
  "purpose" : "To refine valueset for Warfarin + NSAID PDDI-CDS",
  "copyright" : "Attribution CC BY",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "02-Jul-2018",
        "concept" : [
          {
            "code" : "207446",
            "display" : "rimexolone 10 MG/ML Ophthalmic Suspension [Vexol]"
          },
          {
            "code" : "365826",
            "display" : "rimexolone Ophthalmic Suspension [Vexol]"
          },
          {
            "code" : "199115",
            "display" : "rimexolone 10 MG/ML Ophthalmic Suspension"
          },
          {
            "code" : "379299",
            "display" : "rimexolone Ophthalmic Suspension"
          },
          {
            "code" : "1157440",
            "display" : "rimexolone Ophthalmic Product"
          },
          {
            "code" : "1188083",
            "display" : "Vexol Ophthalmic Product"
          }
        ]
      }
    ]
  }
}